Loading
Life sciences · Journal article
International Archives of Otorhinolaryngology · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Head and neck cancer (HNC) management has evolved significantly with the introduction of organ-preservation protocols and changing disease etiology. To analyze site-specific trends in tumor distribution, staging, treatment modality, and survival outcomes using the Surveillance, Epidemiology, and End Results (SEER) program. A retrospective analysis of 288,132 malignant HNC cases from the SEER program (2000–2021) was performed. Survival analyses were restricted to cases diagnosed between 2000 and 2015 to allow for adequate follow-up. The anatomical sites included the salivary gland, larynx, the oral cavity, the lip, the tongue, the nasopharynx, the oropharynx, and the hypopharynx. Trends in tumor proportion, clinical stage, and treatment modality were assessed using linear regression. Five-year survival trends were analyzed using multivariate logistic regression. The proportion of tongue-cancer diagnoses increased by 12.2% (p < 0.001), while that of laryngeal cancer decreased by 10.0% (p < 0.001). Treatment patterns shifted significantly, with the rates of surgery combined with radiation (−11.0%; p < 0.001) and radiation alone (−7.6%; p < 0.001) declining, while that of chemoradiation increased (+16.9%; p < 0.001). The 5-year survival rates improved for hypopharynx (8.5%; p < 0.001), tongue (8.5%; p < 0.001), and oropharynx (8.0%; p < 0.01) cancers. The management of HNC has shifted toward multimodal therapies involving chemotherapy, coinciding with improved survival in pharyngeal and oral subsites. The rising proportion of tongue and oropharyngeal cases may reflect changes in underlying etiologic factors, including human papillomavirus (HPV)-associated disease, although HPV-specific effects cannot be directly assessed in the SEER program.